How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?
Kura K, Stolk W, Basáñez M, Collyer B, de Vlas S, Diggle P, Gass K, Graham M, Hollingsworth T, King J, Krentel A, Anderson R, Coffeng L. How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis? Clinical Infectious Diseases 2024, 78: s93-s100. PMID: 38662701, PMCID: PMC11045024, DOI: 10.1093/cid/ciae021.Peer-Reviewed Original ResearchConceptsMass drug administrationElimination of lymphatic filariasisEfficacious treatment regimensLymphatic filariasisLevels of NTMass drug administration programmesYears of annual treatmentTreatment regimensDrug combinationsTransmission settingsMass drug administration programsDrug AdministrationTreatment coveragePrevalenceTransmission areasMDA coverageBaselineProportion of peopleTreatmentPrevalence thresholdImpact of NTAlbendazoleDiethylcarbamazineHighest infection prevalenceHighest proportion